6540-33-6

Basic information

• Product Name: CYCLOBUTYL-ACETIC ACID
• Synonyms: CYCLOBUTYL-ACETIC ACID;Cyclobutyl;cyclobutylacetic acid(SALTDATA: FREE);2-cyclobutylacetic acid
• CAS NO: 6540-33-6
• Molecular Formula: C₆H₁₀O₂
• Molecular Weight: 114.14
• Product Categories: pharmacetical
• Mol File: 6540-33-6.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 212-213.5℃ (768 Torr)
• Flash Point: 103.9 °C
• Appearance: /
• Density: 1.106 g/cm³
• Vapor Pressure: 0.075mmHg at 25°C
• Refractive Index: 1.4475 (589.3 nm 18.5℃)
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 4.85±0.10(Predicted)
• CAS DataBase Reference: CYCLOBUTYL-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: CYCLOBUTYL-ACETIC ACID(6540-33-6)
• EPA Substance Registry System: CYCLOBUTYL-ACETIC ACID(6540-33-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• HazardClass: IRRITANT
• Hazardous Substances Data: 6540-33-6(Hazardous Substances Data)

Usage

General Description

Cyclobutyl-acetic acid, also known as cyclobutaneacetic acid or 1-cyclobutylacetic acid, is a chemical compound with the molecular formula C6H10O2. It is a carboxylic acid with a cyclobutyl group attached to the acetic acid backbone. Cyclobutyl-acetic acid is used as a building block in the synthesis of various pharmaceuticals and agrochemicals. It has been studied for its potential medicinal properties, including its anti-inflammatory and analgesic effects. CYCLOBUTYL-ACETIC ACID is considered to be of low toxicity and has been used in research and development for potential therapeutic applications.

InChI:InChI=1/C6H10O2/c7-6(8)4-5-2-1-3-5/h5H,1-4H2,(H,7,8)

Upstream product

• 13295-53-9 cyclobutylmethyl 4-methylbenzenesulfonate 
• 17247-58-4 (Bromomethyl)cyclobutane 
• 124-38-9 carbon dioxide 
• 5006-22-4 Cyclobutanecarbonyl chloride 
• 3779-29-1 diethyl cyclobutane-1,1-dicarboxylate 
• 4415-82-1 cyclobutanemethanol 
• 3721-95-7 Cyclobutanecarboxylic acid 
• 63659-30-3 cyclobutylmethyl methanesulfonate 
• 6540-31-4 2-cyclobutylacetaldehyde 
• 4426-03-3 cyclobutyl acetonitrile 

Downstream Products

• 4415-74-1 2-cyclobutylethanol 
• 301186-27-6 (R)-4-benzyl-3-(2-cyclobutylacetyl)oxazolidin-2-one 
• 909717-47-1 (S)-4-Benzyl-3-((S)-2-cyclobutyl-pent-4-enoyl)-oxazolidin-2-one 
• 909717-49-3 (S)-2-Cyclobutyl-pent-4-enoic acid 3,5-bis-trifluoromethyl-benzylamide 
• 1297551-48-4 (+/-)-tert-butyl 3-(3-bromo-4-chlorophenyl)-2-cyclobutylpropanoate 
• 1124212-25-4 N-tert-butyl-3-((4-(4-(2-cyclobutylacetamido)benzoyl)piperazin-1-yl)methyl)benzamide 2,2,2-trifluoroacetate 
• 36206-72-1 2-cyclobutylethyl 4-methylbenzenesulfonate 

Relevant articles and documents

Synthesis of novel shikonin derivatives and pharmacological effects of cyclopropylacetylshikonin on melanoma cells

Despite much research in the last centuries, treatment of malignant melanoma is still challenging because of its mostly unnoticeable metastatic spreading and aggressive growth rate. Therefore, the discovery of novel drug leads is an important goal. In a previous study, we have isolated several shikonin derivatives from the roots of Onosma paniculata Bureau & Franchet (Boraginaceae) which evolved as promising anticancer candidates. β,β-Dimethylacrylshikonin (1) was the most cytotoxic derivative and exhibited strong tumor growth inhibitory activity, in particular, towards melanoma cells. In this study, we synthesized eighteen novel shikonin derivatives in order to obtain compounds which exhibit a higher cytotoxicity than 1. We investigated their cytotoxic potential against various melanoma cell lines and juvenile skin fibroblasts. The most active compound was (R)-1-(1,4-dihydro-5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl cyclopropylacetate (cyclopropylacetylshikonin) (6). It revealed significant stronger tumor growth inhibitory activity towards two melanoma cell lines derived from metastatic lesions (WM164 and MUG-Mel2). Further investigations have shown that 6 induced apoptosis caspase-dependently, increased the protein levels of cleaved PARP, and led to double-stranded DNA breaks as shown by phosphorylation of H2AX. Cell membrane damage and cell cycle arrest were not observed.

CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS

The present invention relates to the use of carboxamide 4-[(4-pyridyl)amino]- pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections.

CARBOXAMIDE INHIBITORS OF TGFB

Certain appropriately substituted forms of pyrimidine having a pyridylamine group at C- 4 of the pyrimidine and an amide group on the pyridine ring are useful in the treatment of conditions associated with excessive TGFB activity.